A vision for vaccines built from fully synthetic tumor-associated antigens: from the laboratory to the clinic.
Cancer cells may be distinguished from normal cells by cell surface displays of aberrant levels and types of carbohydrate domains. Accordingly, these tumor-associated carbohydrate antigens (TACAs) represent promising target structures for the design of anticancer vaccines. Over the past 20 years, our laboratory has sought to use the tools of chemical synthesis to develop TACA-based anticancer vaccine candidates. We provide herein a personal accounting of our laboratory's progress toward the long-standing goal of developing clinically viable fully synthetic carbohydrate-based anticancer vaccines.
Laboratory for Bioorganic Chemistry, Sloan-Kettering Institute for Cancer Research , 1275 York Avenue, New York, New York 10065, United States.
Rebecca M
RM
Wilson
Samuel J
SJ
Danishefsky
D000818:Animals; D015295:Antigens, Tumor-Associated, Carbohydrate / Q000008:administration & dosage / Q000737:chemistry* / Q000276:immunology; D019496:Cancer Vaccines / Q000008:administration & dosage / Q000737:chemistry* / Q000276:immunology; D006801:Humans; D009369:Neoplasms / Q000276:immunology / Q000517:prevention & control*; D014614:Vaccines, Synthetic / Q000008:administration & dosage / Q000737:chemistry* / Q000276:immunology
D015295:Antigens, Tumor-Associated, Carbohydrate; D019496:Cancer Vaccines; D014614:Vaccines, Synthetic